Shares of Health Care sector company Cytokinetics moved 20.2% today, and are now trading at a price of $79.42. The Mid-Cap stock's daily volume was 9,936,146 compared to its average volume of 1,910,175. The S&P 500 index returned a 1.0% performance.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company is based in South San Francisco and has 673 full time employees. Its market capitalization is $9,867,278,336.
19 analysts are following Cytokinetics and have set target prices ranging from $67.0 to $136.0 per share. On average, they have given the company a rating of buy. At today's prices, CYTK is trading -14.89% away from its average analyst target price of $93.32 per share.
Over the last year, CYTK's share price has increased by 94.4%, which represents a difference of 66.0% when compared to the S&P 500. The stock's 52 week high is $80.18 per share whereas its 52 week low is $29.31. Cytokinetics has averaged free cash flows of $-309119166.7 over the last 5 years, with a mean growth rate of -202.6%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.
Cash Flow from Operations ($ k) Capital expenditures ($ k) \
Date Reported
2025 -510,009 24,807
2024 -395,890 3,906
2023 -414,333 1,416
2022 -299,516 11,335
2021 -142,522 48,872
2020 8,943 11,052
Free Cash Flow ($ k) YoY Growth (%)
Date Reported
2025 -534,816 -33.77
2024 -399,796 3.84
2023 -415,749 -33.75
2022 -310,851 -62.41
2021 -191,394 -8975.11
2020 -2,109
